Chimerix (NASDAQ:CMRX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, August 13th. Analysts expect Chimerix to post earnings of ($0.23) per share for the quarter.
Chimerix Trading Down 0.1 %
NASDAQ CMRX opened at $0.84 on Wednesday. Chimerix has a 12 month low of $0.78 and a 12 month high of $1.30. The company’s 50-day moving average price is $0.89 and its 200-day moving average price is $0.98. The stock has a market cap of $75.58 million, a PE ratio of -0.91 and a beta of 1.20.
Analysts Set New Price Targets
Separately, StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Saturday, June 8th.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
- Five stocks we like better than Chimerix
- Health Care Stocks Explained: Why You Might Want to Invest
- Lumen’s Q2: Can AI Revenue Outshine a Mountain of Debt?
- What is the Euro STOXX 50 Index?
- Carry Trade Ending: Recent Market Turbulence and Future Risks
- How to Invest in Small Cap Stocks
- Stocks Slide: Trillions Lost, More Downside Ahead?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.
